Connect with us

Hi, what are you looking for?

Clinical Trials

Reify Health Raises $220M for Platform to Optimize Clinical Trial Recruitment

Reify Health, a company dedicated to shortening clinical trial timelines, announced today that it raised $220 million in a Series C financing round.

Reify Health Raises $220M for Platform to Optimize Clinical Trial Recruitment

Reify Health, a company dedicated to shortening clinical trial timelines, announced today that it raised $220 million in a Series C financing round.

Coatue Management led the round, with Iconiq Growth and Adams Street Partners joining along with existing investors Sierra Ventures and Battery Ventures. The round brings the company’s valuation to $2.2 billion, according to a news release.

Boston-based Reify Health built a foundation for running clinical trials through its StudyTeam and Care Access business entities. StudyTeam optimizes patient recruitment and enrollment, with companies such as Amgen, AstraZeneca, Eli Lilly and more using the platform.

Care Access has conducted the most advanced decentralized trials at scale, Reify Health said, and is the world’s leading decentralized research organization that brings clinical trial infrastructure directly to patients, healthcare providers and communities.

Reify Health said it plans to use the latest funding to fuel its growth and expansion efforts for both the Care Access and StudyTeam business entities.

“What we’re doing, and the future of clinical trials overall, goes beyond decentralized trials,” Reify Health executive chairman Michael Lin said in the release. “We need to have a global healthcare system proactively reaching out to patients everywhere and mobilizing the resources necessary to bring trials to them.”

“Early on, we spent a number of years trying to understand this question: why is clinical research still such a devastating bottleneck on drug development?” added CEO Ralph Passarella. “It was painfully obvious that slow, unpredictable patient enrollment was at the heart of the problem. If we want to consistently enroll trials in three to four months instead of 18 months, there are two key things we must achieve.

“First, we must be able to rapidly identify enough interested patients. Second, we have to make it feasible for those patients to participate in the relevant trial. We built the StudyTeam platform in 2015 to tackle the first part of that future state.”

The post Reify Health raises $220M for platform to optimize clinical trial recruitment appeared first on Drug Discovery and Development.

Seen on Drug Discovery and Development: Article Link

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Exclusives

IoT is transforming healthcare through wearables, SaMD, and AI. MedTech needs strong branding for the efficiency and cost savings this will provide.

Digital Health

The lack of standardization is a huge problem in the diagnosis and tracking of neurological disorders: because they are so complex and often slow...

FDA

System creates 3D models of the heart with unprecedented anatomical details, allowing physicians to better plan and personalize therapeutic interventions

FDA

Linear Health Sciences has received U.S. FDA clearance and Health Canada approval of its Orchid SRV, a tension-activated breakaway safety release valve designed to reduce the...

You May Also Like

Exclusives

Plug “digital healthcare solutions” into Google, and the results are clear: digital tools have taken the healthcare industry by storm. Innovators across the HealthTech...

Exclusives

PRIA clients are provided a high-touch, white-glove service to support their patient access services.

Exclusives

In Delray Beach, Florida, an emerging biopharma company, Cyrano Therapeutics, is planning a clinical trial using approved theophylline via a new intranasal pathway of...

Exclusives

The sky’s the limit for HealthTech PR and looking past traditional strategies to nontraditional avenues for engagement will allow agencies to stand out.